# READY

Source: https://onco.cc/trials/ready-dasatinib/  
OnCo record `ready-dasatinib` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Blocking Src, the kinase that lets prostate cancer cells talk to bone-dissolving cells, did nothing when added to chemotherapy.

## Summary

Src kinase mediates the crosstalk between prostate cancer cells and osteoclasts, and preclinical work suggested that inhibiting it would be synergistic with docetaxel. READY was the test.

It randomised 1,522 men with chemotherapy-naive metastatic castration-resistant prostate cancer to docetaxel and prednisone with dasatinib 100 mg once daily or placebo, blinded to patients, investigators and analysts.

At the final analysis, median follow-up 19.0 months and 914 deaths, median overall survival was 21.5 months (95 percent confidence interval 20.3 to 22.8) with dasatinib and 21.2 months (20.0 to 23.4) with placebo, stratified hazard ratio 0.99 (95.5 percent confidence interval 0.87 to 1.13, p=0.90).

The commonest grade 3 to 4 adverse events with dasatinib against placebo were diarrhoea (58 of 762, 8 percent, against 27 of 760, 4 percent), fatigue (62, 8 percent, against 42, 6 percent) and asthenia (40, 5 percent, against 23, 3 percent). Grade 3 to 4 pleural effusions, the toxicity dasatinib is known for in leukaemia, were uncommon at 10 (1 percent) against three (under 1 percent).

READY belongs with COMET-1, CALGB 90401 and the endothelin trials in the group of bone-microenvironment hypotheses that produced large, well-conducted, completely null trials.

## Fields

- Kind: Trial
- Status: negative
- Last checked: 2026-09-25
- Also known as: READY; CA180-227; dasatinib with docetaxel
- Registry id: NCT00744497
- Phase: 3
- Setting: Chemotherapy-naive metastatic castration-resistant prostate cancer with adequate organ function, stratified by ECOG performance status, bisphosphonate use and urinary N-telopeptide: docetaxel 75 mg/m2 every 3 weeks with prednisone 5 mg twice daily, plus dasatinib 100 mg once daily or placebo, with overall survival as the primary endpoint
- Sponsor: Bristol-Myers Squibb
- Enrolled: 1522
- Result: Median overall survival 21.5 against 21.2 months (stratified hazard ratio 0.99, 95.5 percent confidence interval 0.87 to 1.13, p=0.90): no benefit.
- Outcomes: Overall survival (median): Docetaxel, prednisone and dasatinib 21.5 months vs Docetaxel, prednisone and placebo 21.2 months, HR 0.99
- Replication: Consistent with the other bone-microenvironment failures: COMET-1, CALGB 90401, SWOG S0421 and ENTHUSE M1.

## Sources

- ClinicalTrials.gov NCT00744497: https://clinicaltrials.gov/study/NCT00744497
- READY (Lancet Oncology 2013): https://doi.org/10.1016/S1470-2045(13)70479-0

## Connected records

- cancers: [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Prostate cancer](https://onco.cc/cancers/prostate/)
- technologies: [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/)
- targets: [SRC family kinases](https://onco.cc/targets/src/)
- drugs: [Dasatinib](https://onco.cc/drugs/dasatinib/), [Docetaxel](https://onco.cc/drugs/docetaxel/), [Prednisone](https://onco.cc/drugs/prednisone/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- terms: [Bone metastases and skeletal-related events](https://onco.cc/terms/bone-metastases/), [Castration-resistant prostate cancer (CRPC)](https://onco.cc/terms/castration-resistance/), [Prostate cancer programmes that failed, and what each failure taught](https://onco.cc/terms/prostate-failed-programmes/)
- trials: [CALGB 90401](https://onco.cc/trials/calgb-90401/), [COMET-1](https://onco.cc/trials/comet-1/), [SWOG S0421](https://onco.cc/trials/swog-s0421-atrasentan/)

---
JSON: https://onco.cc/api/v1/entities/ready-dasatinib.json